Advanced Company Research

argenx SE  (ARGX_BR)     €  424.00        (2023-12-08 close)

Industry Biotechnology
Sector Health Care
Main Index BEL20
Company's (investor relations) website Company Website
Next earnings report NaT
Reporting currency EUR
Fiscal year period 01/01-31/12
Reporting cycle Quarter
Last processed report Q4-2021
Market Capitalization (in million) €  21,794
Enterprise value €  21,525
Shares outstanding (in million) 51.5
ROE (Return on Equity) -16.1%
ROA (Return on Assets) -17.4%
EPS (Earnings Per Share) €  -7.92
PE (Price/Earnings) 614.5
Beta 0.68

Implicit value:  € 274.78   Overvalued         Sell 

Implicit value range
Investment advice Sell
Trading advice   (based on moving averages) Sell
Latest StockAdvisor Algorithmic advice    see Return on Advice Graph Buy
Fundamental Strength (scale 0 - 100) 22
Trading Strength (scale 0 - 100) 23
1 year performance 13.22%
52 Weeks range € 320.1 - 491.8
10 Day's Moving Average Downtrend
50 Day's Moving Average Downtrend
200 Day's Moving Average Uptrend
Revenue (last year in million) €  539
5 year Revenue growth (5 year CAGR) 26.86%
Net income (last year in million) €  -408
5 year Net income growth (5 year CAGR) 0%
1 year target €  218.14
3 year target €  213.67
 

Company Description

Argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, ARGX-112 etc. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Luxembourg.

Peers    (More Peer analysis)

argenx SE
Biomarin Pharmaceutical Inc.
Galapagos NV
Incyte Corporation
Moderna, Inc.
MorphoSys AG
Nicox S.A.
Pharming Group N.V.
 

Yearly Financials     (More Yearly Financials)
* Forecasted by Stockadvisor algorithm

Description 2020 2021 2022 2023 * 2024 * 2025 *
Revenue €  23 €  539 €  619 €  574 €  575 €  590
Net income €  -323 €  -408 €  36 €  48 €  65 €  78
EPS €  -3.22 €  -7.92 €  0.69 €  0.94 €  1.27 €  1.26
PE -75.10 -39.80 406.48 292.77 171.72 172.23
Prices eoy €  242.00 €  315.30 €  280.39 €  274.78 €  218.14 €  217.24
Dividend €  0.00 €  0.00 €  0.00 €  0.00 €  0.00 €  0.00
Div-% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Quarterly Financials     (More Quarterly Financials)
* Forecasted by Stockadvisor algorithm

Description Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23
Revenue €  153 €  195 €  141 €  129 €  122 €  139 €  164 €  150
Net income €  1 €  12 €  23 €  0 €  0 €  10 €  25 €  13
EPS €  0.02 €  0.23 €  0.44 €  0.00 €  0.00 €  0.19 €  0.49 €  0.26
PE -36.50 -31.01 -66.77 406.48 418.05 381.69 364.86 292.77
Prices eoq €  282.50 €  357.50 €  368.50 €  280.39 €  282.68 €  242.82 €  250.29 €  274.78
 




Description Look into
Annual report 2016
Annual report 2017
Annual report 2018
Annual report 2019
Annual report 2020

Source: ReportFinder    







Graphs   (More Graphs)

Ratios vs Benchmarks   (More ratios & stats)





NORM
Description Actuals Progressive Neutral Conservative
Solvency 73.4% < 25% 25-35% > 35%
ROE (return on equity) -23.7% > 12% 10-12% < 10%
ROA (return on assets) -17.4% > 5% 5% < 5%
Current ratio 6.3 < 1 1-1.5 > 1.5
Turnover rate 80.8 < 1 1-1.5 > 1.5
WACC 11.96% > 10% 10% < 10%
Beta 0.68 > 1 1 < 1